233 related articles for article (PubMed ID: 23462656)
1. Salivary morbidity and quality of life following radioactive iodine for well-differentiated thyroid cancer.
Dingle IF; Mishoe AE; Nguyen SA; Overton LJ; Gillespie MB
Otolaryngol Head Neck Surg; 2013 May; 148(5):746-52. PubMed ID: 23462656
[TBL] [Abstract][Full Text] [Related]
2. Clinical predictors of quality of life in patients with initial differentiated thyroid cancers.
Almeida JP; Vartanian JG; Kowalski LP
Arch Otolaryngol Head Neck Surg; 2009 Apr; 135(4):342-6. PubMed ID: 19380354
[TBL] [Abstract][Full Text] [Related]
3. The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the M. D. Anderson dysphagia inventory.
Chen AY; Frankowski R; Bishop-Leone J; Hebert T; Leyk S; Lewin J; Goepfert H
Arch Otolaryngol Head Neck Surg; 2001 Jul; 127(7):870-6. PubMed ID: 11448365
[TBL] [Abstract][Full Text] [Related]
4. Radioiodine-Induced Salivary Gland Damage Detected by Ultrasonography in Patients Treated for Papillary Thyroid Cancer: Radioactive Iodine Activity and Risk.
Horvath E; Skoknic V; Majlis S; Tala H; Silva C; Castillo E; Whittle C; Niedmann JP; González P
Thyroid; 2020 Nov; 30(11):1646-1655. PubMed ID: 32370663
[No Abstract] [Full Text] [Related]
5. Prophylactic effect of pilocarpine on acute sialadenitis following radioactive iodine therapy in thyroid cancer patients.
Choi EK; Oh JK; Chung YA; Jeong H; Choi H; Jo K
Int J Med Sci; 2024; 21(3):492-495. PubMed ID: 38250604
[No Abstract] [Full Text] [Related]
6. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms.
Jeong SY; Kim HW; Lee SW; Ahn BC; Lee J
Thyroid; 2013 May; 23(5):609-16. PubMed ID: 23153322
[TBL] [Abstract][Full Text] [Related]
7. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation.
Grewal RK; Larson SM; Pentlow CE; Pentlow KS; Gonen M; Qualey R; Natbony L; Tuttle RM
J Nucl Med; 2009 Oct; 50(10):1605-10. PubMed ID: 19759114
[TBL] [Abstract][Full Text] [Related]
8. The relationship between depressive symptoms, quality of life, and swallowing function in head and neck cancer patients 1 year after definitive therapy.
Lin BM; Starmer HM; Gourin CG
Laryngoscope; 2012 Jul; 122(7):1518-25. PubMed ID: 22467530
[TBL] [Abstract][Full Text] [Related]
9. [Changes in quality of life and related factors in thyroid cancer patients with radioactive iodine remnant ablation].
Yoo SH; Choi-Kwon S
J Korean Acad Nurs; 2013 Dec; 43(6):801-11. PubMed ID: 24487996
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors of
Hollingsworth B; Senter L; Zhang X; Brock GN; Jarjour W; Nagy R; Brock P; Coombes KR; Kloos RT; Ringel MD; Sipos J; Lattimer I; Carrau R; Jhiang SM
J Clin Endocrinol Metab; 2016 Nov; 101(11):4085-4093. PubMed ID: 27533304
[TBL] [Abstract][Full Text] [Related]
11. Dysphagia after nonsurgical head and neck cancer treatment: patients' perspectives.
Wilson JA; Carding PN; Patterson JM
Otolaryngol Head Neck Surg; 2011 Nov; 145(5):767-71. PubMed ID: 21746839
[TBL] [Abstract][Full Text] [Related]
12. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach.
Dorn R; Kopp J; Vogt H; Heidenreich P; Carroll RG; Gulec SA
J Nucl Med; 2003 Mar; 44(3):451-6. PubMed ID: 12621014
[TBL] [Abstract][Full Text] [Related]
13. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.
Tuttle RM; Leboeuf R; Robbins RJ; Qualey R; Pentlow K; Larson SM; Chan CY
J Nucl Med; 2006 Oct; 47(10):1587-91. PubMed ID: 17015892
[TBL] [Abstract][Full Text] [Related]
14. Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer.
Almeida JP; Sanabria AE; Lima EN; Kowalski LP
Head Neck; 2011 May; 33(5):686-90. PubMed ID: 21484917
[TBL] [Abstract][Full Text] [Related]
15. Impact of dysphagia on quality-of-life in nasopharyngeal carcinoma.
Lovell SJ; Wong HB; Loh KS; Ngo RY; Wilson JA
Head Neck; 2005 Oct; 27(10):864-72. PubMed ID: 16114007
[TBL] [Abstract][Full Text] [Related]
16. Impact of dysphagia on quality of life after treatment of head-and-neck cancer.
Nguyen NP; Frank C; Moltz CC; Vos P; Smith HJ; Karlsson U; Dutta S; Midyett A; Barloon J; Sallah S
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):772-8. PubMed ID: 15708256
[TBL] [Abstract][Full Text] [Related]
17. Sialadenitis following I-131 therapy for thyroid carcinoma: concise communication.
Allweiss P; Braunstein GD; Katz A; Waxman A
J Nucl Med; 1984 Jul; 25(7):755-8. PubMed ID: 6737074
[TBL] [Abstract][Full Text] [Related]
18. Quality of life impact of external beam radiotherapy for advanced thyroid carcinoma.
Gal TJ; Streeter M; Burris J; Kudrimoti M; Ain KB; Valentino J
Thyroid; 2013 Jan; 23(1):64-9. PubMed ID: 22971127
[TBL] [Abstract][Full Text] [Related]
19. Xerostomia after treatment for oral and oropharyngeal cancer using the University of Washington saliva domain and a Xerostomia-Related Quality-of-Life Scale.
Rogers SN; Johnson IA; Lowe D
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):16-23. PubMed ID: 19679404
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
